<DOC>
	<DOCNO>NCT00380172</DOCNO>
	<brief_summary>The purpose study evaluate effect vision subject AMD receive active placebo treatment MIRA-1 study .</brief_summary>
	<brief_title>Long-Term Efficacy AMD Rheopheresis North America</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Must participate treatment arm MIRA1 trial complete 4 treatment 6 9 month follow visit . Dry AMD least one eye . Available study duration 12 month . Weigh &gt; 110 lb . If lipidlowering medication must remain duration trial . If , must agree initate trial . Normal Pt/ PTT . If coumadin , discretion investigator . Must highly motivate , alert orient , able provide consent . Agree discontinue current ocular vitamin regimen take uniform supplement provide sponsor . Both eye wet AMD . Condition limit view fundus . Poor general health unstable disease . HCT &lt; 35 % , evidence active bleeding , platelet count &lt; 100000 K/uL , prolong Pt/ PTT , significant coagupapathies . significant cardiac problem . Uncontrolled hypertension . History CVA TIA within year . Significant hepatic , renal , pulmonary disease , insulin dependent diabetes . Allergy fluorescein sodium indocyanine green ( ICG ) , heparin , ACDA , local anesthetic , adhesive tape . Pregnant breastfeed woman , woman childbearing potential use chemical mechanical contraception . Investigation trial within 30 day . Major surgery within 30 day . Unwilling adhere visit schedule . Unstable medical psychological condition .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>AMD</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Retinal Degeneration</keyword>
</DOC>